Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) Other Non Operating Income (2022 - 2025)

Historic Other Non Operating Income for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to $292000.0.

  • Taysha Gene Therapies' Other Non Operating Income rose 46049.38% to $292000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $286000.0, marking a year-over-year increase of 10043.55%. This contributed to the annual value of -$110000.0 for FY2024, which is 10031.68% down from last year.
  • Per Taysha Gene Therapies' latest filing, its Other Non Operating Income stood at $292000.0 for Q3 2025, which was up 46049.38% from $273000.0 recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' Other Non Operating Income registered a high of $100.5 million during Q3 2023, and its lowest value of -$65.7 million during Q4 2023.
  • Moreover, its 4-year median value for Other Non Operating Income was -$4500.0 (2022), whereas its average is $2.5 million.
  • Data for Taysha Gene Therapies' Other Non Operating Income shows a peak YoY increase of 1004570000.0% (in 2023) and a maximum YoY decrease of 109553333.33% (in 2023) over the last 5 years.
  • Taysha Gene Therapies' Other Non Operating Income (Quarter) stood at -$6000.0 in 2022, then tumbled by 1095533.33% to -$65.7 million in 2023, then surged by 99.73% to -$177000.0 in 2024, then skyrocketed by 264.97% to $292000.0 in 2025.
  • Its Other Non Operating Income stands at $292000.0 for Q3 2025, versus $273000.0 for Q2 2025 and -$102000.0 for Q1 2025.